|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Baehner FL et al. Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. San Antonio Breast Cancer Symposium 2006;Abstract 45.
Habel LA et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(3):R25. Abstract
Jones S et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 40.
Mina L et al. Predicting response to primary chemotherapy: Gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2006;[Epub ahead of print]. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Paik S et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients — NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003;82(Suppl 1):10. No abstract available
Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Proc ASCO 2006;Abstract 522.
Sparano JA et al. Clinical application of molecular profiling in breast cancer. Future Oncol 2005;1(4):485-96. Abstract
Sparano JA et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium 2005;Abstract 48.
 |
 |
